IDO inhibitors

1. A compound of Formula (I)

wherein:

W is CR 4 or N;

V is CR 5 or N, and

Y is CR 6 or N;

{circle around (A)} is optionally substituted phenyl or optionally substituted 5 to 7-membered monocyclic heteroaryl;

R 1 is COOH, tetrazol-5-yl, —NHSO 2 R 20 ,

—CONHSO 2 R 21 , —CONHCOOR 22 , or —SO 2 NHCOR 23 ;

R 2 and R 3 are independently H, hydroxy, optionally substituted C 1 -C 6 alkyl, halo, N(C 1 -C 6 alkyl) 2 or optionally substituted C 1 -C 6 alkoxy;

R 4 , R 5 and R 6 are independently H, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, C 1 -C 6 alkanoyl, halo, CN, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkenyl, optionally substituted C 3 -C 8 cycloalkyl, C 2 -C 6 -alken-dienyl, dihydroindenyl, optionally substituted C 1 -C 6 alkoxy, or OH,

wherein the optional substituents, where possible, are 1-3 groups selected from halo, C 3 -C 8 cycloalkyl, aryl, optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, di-C 1 -C 6 -alkylamino or cyano;

R 7 is H, optionally substituted aryl, optionally substituted bicyclic carbocyclyl, optionally substituted 5- to 7-membered monocyclic heteroaryl, optionally substituted 5- to 7-membered monocyclic heterocyclic, optionally substituted C 1 -C 6 alkoxy, optionally substituted arylalkyl, optionally substituted C 1 -C 9 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 8 cycloalkyl, or optionally substituted C 5 -C 8 cycloalkenyl,

wherein the optional substituents, where possible, are 1-3 groups selected from H, C 1 -C 6 alkyl, aryl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 5- to 7-membered monocyclic heterocyclic, C 2 -C 6 alkynyloxy(C 1 -C 6 alkyl) 0-1 , halo, halo-substituted aryl, oxo, trihalo-C 1 -C 6 -alkyl, or OR 19 ,

where R 19 is H, C 1 -C 6 alkyl, C 2 -C 6 alkyl, or C 2 -C 6 alkynyl;

R 8 is optionally substituted aryl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 1 -C 6 alkyl, optionally substituted 5- to 7-membered monocyclic heterocyclic, optionally substituted 5- to 7-membered monocyclic heteroaryl, optionally substituted 8- to 10-membered bicyclic heteroaryl, optionally substituted C 1 -C 6 alkoxycarbonyl 5- to 7-membered monocyclic heteroaryl, R 24 CO—, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl or optionally substituted C 5 -C 8 cycloalkenyl,

wherein the optional substituents, where possible, are 1-2 groups selected from H, optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, halo, optionally substituted C 1 -C 6 -alkoxy, cyano, 5 to 7-membered monocyclic heteroaryl, NH 2 CO—, di-C 1 -C 6 -alkylamino, aminosulfonyl, 5 to 7-membered monocyclic heterocyclo, hydroxy, C 1 -C 6 alkylsulfonyl, azido, or aryl;

R 19 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 20 is optionally substituted C 1 -C 6 alkyl, optionally substituted phenyl, CF 3 , CF 2 CF 3 or CH 2 CF 3 ;

R 21 is optionally substituted C 1 -C 6 alkyl, or optionally substituted C 3 -C 8 cycloalkyl;

R 22 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 23 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 24 is optionally substituted aryl-C 1 -C 6 -alkyl, C 1 -C 6 alkylaryl, aryl-C 1 -C 6 -alkyl(hydroxy), or optionally substituted C 1 -C 6 alkyl;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

2. The compound as defined in claim 1 wherein:

W is CR 4 ;

V is CR 5 ;

Y is CR 6 or N;

R 4 is H;

R 5 is H; and

R 6 is H, halo, optionally substituted C 1 -C 6 -alkyl, optionally substituted C 2 -C 6 -alkenyl, optionally substituted C 2 -C 6 alken-dienyl, C 3 -C 8 cycloalkyl or C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

3. The compound as defined in claim 1 wherein {circle around (A)} is phenyl, and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

4. The compound as defined in claim 1 wherein:

R 1 is COOH, tetrazol-5-yl, —NHSO 2 R 20 or CONHSO 2 R 21 ;

R 2 is H, halo, hydroxy, optionally substituted C 1 -C 6 -alkyl or C 1 -C 6 alkoxyl; and

R 3 is H or C 1 -C 6 alkoxy;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

5. The compound as defined in claim 1 wherein:

R 7 is aryl, optionally substituted C 1 -C 9 -alkyl, optionally substituted C 1 -C 6 alkylaryl, C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl, C 3 -C 8 cycloalkylaryl, optionally substituted C 3 -C 8 -cycloalkyl or optionally substituted aryl C 1 -C 6 -alkyl,

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

6. The compound as defined in claim 1 wherein:

R 8 is optionally substituted C 1 -C 6 alkylaryl, optionally substituted aryl, optionally substituted C 3 -C 8 cycloalkylaryl, optionally substituted C 3 -C 8 -cycloalkyl-C 1 -C 6 alkyl, optionally substituted 5- to 7-membered heterocyclic, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl-C 1 -C 6 -alkyl, C 1 -C 6 alkoxyaryl, C 1 -C 6 -alkoxy(C 1 -C 6 -alkyl)aryl, C 3 -C 8 cycloalkyl, optionally substituted C 1 -C 6 -alkyl-C 3 -C 8 -cycloalkyl, optionally substituted C 1 -C 6 alkanoyl, di-C 1 -C 6 -alkylaminophenyl or C 2 -C 6 alkenyl,

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

7. A compound of Formula (II)

wherein:

Y is CR 6 or N;

R 1 is COOH, tetrazol-5-yl,

R 2 is H, optionally substituted C 1 -C 6 alkyl, OH, optionally substituted C 1 -C 6 alkoxy or CF 3 ;

R 3 is H, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy;

R 4 is H;

R 5 is H;

R 6 is H, optionally substituted aryl C 1 -C 6 -alkyl, optionally substituted aryl-C 2 -C 6 -alkenyl, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl or optionally substituted C 2 -C 6 -alken-dienyl,

R 7 is selected from optionally substituted aryl, optionally substituted C 1 -C 6 alkylaryl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 1 -C 8 alkyl, optionally substituted aryl-C 1 -C 6 -alkyl, C 3 -C 8 cycloalkylaryl, 2,2-C 1 -C 6 -dialkyldihydrobenzofuran

optionally substituted C 1 -C 6 -alkyl(aryl)-C 1 -C 6 -alkyl, C 2 -C 6 alkynyloxy(C 1 -C 6 alkyl)aryl, optionally substituted 5 to 7-membered monocyclic heterocyclic or optionally substituted C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl;

R 8 is optionally substituted C 1 -C 6 alkylaryl, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, optionally substituted aryl-C 1 -C 6 -alkyl, optionally substituted C 1 -C 6 alkoxyaryl, optionally substituted C 1 -C 6 -alkoxy(C 1 -C 6 -alkyl)aryl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 3 -C 8 cycloalkylaryl, optionally substituted C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl, optionally substituted 5- to 7-membered monocyclic heterocyclic, optionally substituted C 1 -C 6 -alkyl-C 3 -C 8 -cycloalkyl, optionally substituted C 1 -C 6 alkanoylaryl, C 1 -C 6 dialkylaminoaryl, dihydroindenyl, optionally substituted C 2 -C 6 alkenyl, or optionally substituted C 2 -C 6 alkynyl;

and/or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a stereoisomer thereof.

8. The compound as defined in claim 7 wherein:

R 1 is COOH, tetrazol-5-yl, CONHSO 2 CH 3 or —NHSO 2 CH 3 ;

R 2 is H, Cl, F, OH, or CH 3 O; and

R 3 is H or CH 3 O;

and/or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a stereoisomer thereof.

9. The compound according to claim 1 wherein the IC 50 in the HEK Human IDO-1 assay is <10 nM.

10. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

11. A method of inhibiting activity of indoleamine 2,3-dioxygenase comprising contacting said indoleamine 2,3-dioxygenase with a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.